Intertek to open new European immunochemistry lab

Skip to Navigation


  • Published: Jun 5, 2015
  • Author: Jon Evans
  • Source: Intertek
  • Channels: Ion Chromatography / Detectors / Laboratory Informatics / Electrophoresis / Gas Chromatography / Sample Preparation / Proteomics & Genomics / HPLC / Chemometrics & Informatics / UV/Vis Spectroscopy / NMR Knowledge Base / Proteomics / Infrared Spectroscopy / Atomic / Base Peak / X-ray Spectrometry / MRI Spectroscopy / Raman

The UK testing and inspection company Intertek has announced plans to open a new European immunochemistry laboratory. This will provide bioanalytical support for clients’ clinical and pre-clinical immunogenicity and pharmacokinetic (PK) studies in biologic medicines.

The new 10,000 square foot facility will be operated from Intertek’s biologics centre of excellence in Manchester, UK. It will deliver world class scientific support to clients focused on clinical and pre-clinical development of biologic medicines such as monoclonal antibodies, proteins and biosimilars.

The expansion not only builds on the existing service at Manchester, but provides clients with access to large molecule bioanalytical support in both Europe and the US. This facility mirrors the Intertek San Diego immunochemistry facility, which was expanded last year, and will provide global clients with access to specific methods operated from both facilities, requiring no further local validation.

This expansion reflects the fast growth of the global biopharmaceutical market over the past decade and the predicted future growth, particularly in the development of novel therapeutic antibodies. Accompanying this growth in the sector is the fast growth in demand for outsourcing services, including bioanalytical support.

‘Expanding our large molecule bioanalytical capability in Europe enables us to be more responsive to the needs of our clients who increasingly seek global service support from regional locations,’ said Chetan Parmar, senior vice president of Intertek Life Sciences.

‘This expansion will help meet many challenges that our clients face throughout increasingly complex biologic drug development,’ said Ashleigh Wake, biopharmaceutical services leader, UK, for Intertek. ‘The clinical and pre-clinical bioassay capability complements our strengths in protein analysis and biological activity testing.’

Social Links

Share This Links

Bookmark and Share


Suppliers Selection
Societies Selection

Banner Ad

Click here to see
all job opportunities

Copyright Information

Interested in separation science? Visit our sister site

Copyright © 2018 John Wiley & Sons, Inc. All Rights Reserved